- Home
- PTCT vs MAC Comparison
PTCT vs MAC Comparison
Compare PTCT & MAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTCT
- MAC
- Stock Information
- Founded
- PTCT 1998
- MAC 1964
- Country
- PTCT United States
- MAC United States
- Employees
- PTCT N/A
- MAC N/A
- Industry
- PTCT Biotechnology: Pharmaceutical Preparations
- MAC Real Estate Investment Trusts
- Sector
- PTCT Health Care
- MAC Real Estate
- Exchange
- PTCT Nasdaq
- MAC Nasdaq
- Market Cap
- PTCT 4.1B
- MAC 4.3B
- IPO Year
- PTCT 2013
- MAC 1994
- Fundamental
- Price
- PTCT $50.57
- MAC $18.14
- Analyst Decision
- PTCT Buy
- MAC Hold
- Analyst Count
- PTCT 14
- MAC 12
- Target Price
- PTCT $67.14
- MAC $18.95
- AVG Volume (30 Days)
- PTCT 1.5M
- MAC 1.9M
- Earning Date
- PTCT 08-07-2025
- MAC 08-11-2025
- Dividend Yield
- PTCT N/A
- MAC 3.98%
- EPS Growth
- PTCT N/A
- MAC N/A
- EPS
- PTCT 7.72
- MAC N/A
- Revenue
- PTCT $1,764,929,000.00
- MAC $1,102,850,000.00
- Revenue This Year
- PTCT $119.89
- MAC $12.20
- Revenue Next Year
- PTCT N/A
- MAC N/A
- P/E Ratio
- PTCT $6.55
- MAC N/A
- Revenue Growth
- PTCT 96.00
- MAC 48.88
- 52 Week Low
- PTCT $30.41
- MAC $12.48
- 52 Week High
- PTCT $58.38
- MAC $22.27
- Technical
- Relative Strength Index (RSI)
- PTCT 56.09
- MAC 62.69
- Support Level
- PTCT $48.09
- MAC $17.02
- Resistance Level
- PTCT $54.24
- MAC $17.51
- Average True Range (ATR)
- PTCT 2.37
- MAC 0.55
- MACD
- PTCT 0.19
- MAC 0.04
- Stochastic Oscillator
- PTCT 66.83
- MAC 96.15
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
About MAC Macerich Company (The)
Macerich invests in premium mall assets. The company owns 29 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with two power centers and seven other real estate assets. The company's total portfolio has 42.1 million square feet of gross leasable area and averaged $837 sales per square foot over the 12 months ended in March 2025.